159 - Whole Genome Sequencing Surveillance for Infection Prevention: Promises and Barriers

Friday, October 18, 2024

1:45 PM – 3:00 PM US PT

Location: 515 B

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Costi Sifri, MD (he/him/his)

Professor, Director of Hospital Epidemiology
University of Virginia School of Medicine
Charlottesville, VA, United States
Alexander Sundermann, DrPH, CIC, FAPIC

Assistant Professor
University of Pittsburgh
Pittsburgh, PA, United States

Faculty(s)

Lee Harrison, MD

Professor of Medicine and Epidemiology
University of Pittsburgh
Pittsburgh, PA, United States
Lilian Abbo, MD, MBA (she/her/hers)

Professor of Infectious Diseases; Associate Chief Medical Officer in Infectious Diseases
Department of Medicine, Division of Infectious Disease
University of Miami Miller School of Medicine, Jackson Health System
Aventura, FL, United States
Emily Snavely, PhD, D(ABMM) (she/her/hers)

Associate Director, Clinical Microbiology
University of Virginia Health

Disclosure(s):

Costi Sifri: No financial relationships to disclose

Alexander Sundermann, DrPH, CIC, FAPIC: OpGen: Honoraria ()

Lee Harrison, MD: GSK: Advisor/Consultant; Merck: Advisor/Consultant; Pfizer: Advisor/Consultant; Sanofi: Advisor/Consultant

Lilian M. Abbo, MD, MBA: No financial relationships to disclose

Emily Snavely, PhD, D(ABMM): No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the impact of whole-genome sequencing (wgs) surveillance on patient safety by reviewing case studies and assessing the requirements for a successful program implementation;
describe the effectiveness of in-house funded wgs surveillance programs in enhancing patient safety;
recognize key operational aspects such as proficiency, workflow, quality control, and regulatory frameworks associated with wgs surveillance, focusing on addressing challenges and facilitating successful implementation.

Presentations:

1:45 PM – 2:10 PM US PT

Genomic Surveillance: The Future of Infection Prevention in Hospitals
Speaker: Lee Harrison, MD – University of Pittsburgh
2:10 PM – 2:35 PM US PT

A case study in developing an in-house funded WGS surveillance program
Speaker: Lilian M. Abbo, MD, MBA (she/her/hers) – University of Miami Miller School of Medicine, Jackson Health System
2:35 PM – 3:00 PM US PT

Peaking inside the black box: practical issues of WGS surveillance
Speaker: Emily Snavely, PhD, D(ABMM) (she/her/hers) – University of Virginia Health